A PHASE III PROSPECTIVE DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ADJUVANT MEDI4736 IN COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER
A Lung Immunotherapy NSCLC Consortium (LINC) Trial of the CCTG, IFCT, CEEOG, NCI-Naples, NVALT, KCSG, ALTG and NHMRC CTC, SLCG, WJOG,
CCTG Protocol Number: BR.31
IFCT Protocol Number: IFCT1401